文献速递外周动脉疾病

直接口服抗凝药与华法林在慢性肢体威胁性缺血中的比较

Comparison of direct oral anticoagulants and warfarin in chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2024-01-24

单中心回顾性队列研究纳入141例慢性肢体威胁性缺血血运重建后出院处方阿哌沙班、利伐沙班或华法林的患者,1年主要不良肢体事件、主要不良心血管事件及全因死亡率两组无显著差异,华法林组1年ISTH大出血发生率显著更高。

要点

  • 华法林组与DOAC组1年主要不良肢体事件发生率无显著差异(36.7% vs 33.7%,RR 1.09,95%CI 0.53-2.25,P=.72)。
  • 华法林组1年ISTH大出血发生率显著高于DOAC组(16.3% vs 4.3%,RR 3.76,95%CI 1.07-13.19,P=.015)。
  • 1年主要不良心血管事件和全因死亡率两组无显著差异。

核心结论

  • 在慢性肢体威胁性缺血血运重建后出院处方阿哌沙班、利伐沙班或华华法林的患者中,主要不良肢体事件、主要不良心血管事件或全因死亡率无差异。
  • 华法林组1年ISTH大出血入院显著高于DOAC组。
  • 随机试验可能证实这些发现。

研究设计与样本

  • 单中心、观察性、回顾性队列研究。
  • 纳入18岁及以上、因慢性肢体威胁性缺血、静息痛或组织缺损接受血管内或开放血运重建、随后处方阿哌沙班、利伐沙班或华法林的患者。
  • 2017年1月1日至2022年9月20日共141例患者符合纳入和排除标准并接受回顾。
  • 中位年龄67岁,92例处方阿哌沙班或利伐沙班,49例处方华法林;42例接受三联抗血栓治疗,88例双联抗血栓治疗,13例抗凝单药治疗。

主要发现

  • 主要终点1年主要不良肢体事件(包括踝上截肢或主要指数肢体再干预)在华法林组发生率为36.7%,DOAC组为33.7%(RR 1.09,95%CI 0.53-2.25,P=.72)。
  • 次要终点1年主要不良心血管事件在华法林组为10.2%,DOAC组为4.3%(RR 2.35,95%CI 0.60-9.18,P=.18)。
  • 1年全因死亡率在华法林组为26.5%,DOAC组为16.3%(RR 1.63,95%CI 0.70-3.78,P=.15)。
  • 安全性次要终点1年ISTH大出血在华法林组为16.3%,DOAC组为4.3%(RR 3.76,95%CI 1.07-13.19,P=.015)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The role of direct oral anticoagulants (DOACs) in chronic limb-threatening ischemia after revascularization is unknown. Current evidence-based guidelines do not provide clear guidance on the role of anticoagulation or the selection of anticoagulant. Current practice is highly varied and based on provider and patient preference. The purpose of this study was to measure the impact of different anticoagulants on the incidence of major adverse limb events (MALEs) after revascularization for chronic limb-threatening ischemia, major adverse cardiovascular events (MACEs), all-cause mortality, and hospitalization for major bleeding events. METHODS: This was a single-center, observational, retrospective cohort study. Subjects were eligible if they were 18 years or older; underwent endovascular or open revascularization for chronic limb-threatening ischemia, rest pain, or tissue loss; and were subsequently prescribed apixaban, rivaroxaban, or warfarin. The primary end point was the incidence of MALEs, including above-ankle amputation or major index-limb reintervention, within 1 year of index event. Secondary end points included the rate of all-cause mortality, MACEs, and incidence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding. RESULTS: From January 1, 2017, to September 20, 2022, 141 patients met the inclusion and exclusion criteria and were reviewed. The median age was 67 years, with 92 patients prescribed apixaban or rivaroxaban and 49 patients prescribed warfarin. Of these, 42 patients were prescribed triple antithrombotic therapy, 88 dual antithrombotic therapy, and 13 anticoagulant monotherapy. The primary outcome of 1-year MALEs occurred in 36.7% of the warfarin group and 33.7% of the DOAC group (relative risk [RR], 1.09; 95% CI, 0.53-2.25; P = .72). Secondary outcomes of 1-year MACEs (10.2% vs 4.3%; RR, 2.35; 95% CI, 0.60-9.18; P = .18) and 1-year all-cause mortality (26.5% vs 16.3%; RR, 1.63; 95% CI, 0.70-3.78; P = .15) did not differ between the groups. The secondary safety outcome of 1-year ISTH major bleeding occurred in 16.3% of the warfarin group and 4.3% of the DOAC group (RR, 3.76; 95% CI, 1.07-13.19; P = .015). CONCLUSIONS: In patients with chronic limb-threatening ischemia who were revascularized and prescribed anticoagulation with apixaban, rivaroxaban, or warfarin on discharge, no difference in MALEs, MACEs, or all-cause mortality was found. However, 1-year admissions for ISTH major bleeding were significantly higher among patients prescribed warfarin. A randomized trial may confirm these findings.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Rockhold M, Kunkel L, Lacoste JL, et al. Comparison of direct oral anticoagulants and warfarin in chronic limb-threatening ischemia. J Vasc Surg. 2024. PMID: 38278371. doi:10.1016/j.jvs.2024.01.196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。